Loading company…
Scienpharm researches and develops generic and new drugs, including products for cardiovascular, oncology, and diabetes fields.
Founded in 2009 and based in Shanghai, China, Scienpharm develops generic drugs and new drugs, including apixaban, ibrutinib, and vildagliptin. It has R&D centers in Haimen, Jiangsu, and a GSP-certified drug operations platform and API production base in Mingxi, Fujian. As of 2024, its research and development team had more than 150 employees, and the company had CNAS laboratory accreditation. It closed a strategic investment in January 2024.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in